Can a new peptide promote lumbar spinal fusion? 5 key notes

Spine

A new study published in the Journal of Neurosurgery: Spine examines a new peptide to promote lumbar spinal fusion.

The study authors examined 24 patients with single-level degenerative disorders requiring transforaminal lumbar interbody fusion. The patients were either in the control group, Prefix 150 group and Prefix 750 group. The patients in the Prefix group received the B2A peptide-enhanced ceramic granules; the patients in the control group received autogenous iliac crest bone graft.

 

Here are five things to know from the study:

 

1. One year after surgery, the radiographic fusion rates were:

 

• Prefix 750: 100 percent
• Control: 78 percent
• Prefix 150: 50 percent

 

2. Six weeks after surgery, the average Oswestry Disability Index score was:

 

• Prefix 750: 27.7
• Control: 41
• Prefix 150: 32.2

 

3. One year after surgery, the average ODI scores were:

 

• Prefix 750: 31.1
• Control: 24.4
• Prefix 150: 29.7

 

4. The complications were evenly distributed between all three groups.

 

5. The study authors concluded Prefix was a safe alternative to autogenous ICBG, and both groups demonstrated comparable improvements for ODI after one year.

 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Podcast

Featured Whitepapers